Working… Menu

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00140049
Recruitment Status : Completed
First Posted : August 31, 2005
Last Update Posted : February 18, 2021
Information provided by (Responsible Party):
Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )

No Study Results Posted on for this Study
Recruitment Status : Completed
Primary Completion Date : No date given
Actual Study Completion Date : July 2006